Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0NU8J
|
|||
| Drug Name |
Belzutifan
|
|||
| Synonyms |
MK-6482; PT2977
Click to Show/Hide
|
|||
| Indication | Von hippel-lindau disease [ICD-11: 5A75; ICD-10: E27.5; ICD-9: 759.6] | Approved | [1] | |
| Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64; ICD-9: 189] | Phase 3 | [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [3] | ||
| Company |
Merck & Co.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H12F3NO4S
|
|||
| Canonical SMILES |
CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O
|
|||
| InChI |
1S/C17H12F3NO4S/c1-26(23,24)12-3-2-11(13-14(12)17(22)16(20)15(13)19)25-10-5-8(7-21)4-9(18)6-10/h2-6,15-17,22H,1H3/t15-,16-,17+/m1/s1
|
|||
| InChIKey |
LOMMPXLFBTZENJ-ZACQAIPSSA-N
|
|||
| CAS Number |
CAS 1672668-24-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hypoxia-inducible factor 2 alpha (HIF-2A) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Pathways in cancer | |||
| Renal cell carcinoma | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 215383. | |||
| REF 2 | ClinicalTrials.gov (NCT04586231) A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011). U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.